17 May 2016 - This viewpoint describes differences between various cancer value frameworks and provides recommendations for improving them for clinicians, patients, and payers.

In recent years, novel cancer therapies have improved the expected survival of patients but have also increased treatment costs. As a result of these increases, patients are concerned about increasing out-of-pocket costs, clinicians must assess whether “do no harm” includes patient financial harm, and payers want to know if novel therapies are worth the cost.

For more details, go to: http://jama.jamanetwork.com/article.aspx?articleID=2521978